Source: SKS Technologies [LinkedIn]
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • SKS Technologies Group (SKS) has received a formal acceptance of approximately $10 million to supply the audio visual package for the new Footscray Hospital, in Melbourne
  • It is to design, supply and install the Audio-Visual package related to the Private Public Partnership for the hospital
  • Construction of the $1.5 billion new Footscray Hospital is now underway
  • Matthew Jinks, CEO of SKS Technologies, says this formal acceptance is a significant achievement for the company
  • SKS Technologies Group Limited (SKS) last traded at $0.18 per share before market open on December 23

SKS Technologies Group (SKS) has received a formal acceptance of approximately $10 million to supply the audio visual package for the new Footscray Hospital, in Melbourne.

Construction of the $1.5 billion new Footscray Hospital is now underway, with SKS chosen to design, supply and install the Audio-Visual package related to the Private Public Partnership for the hospital.

The hospital will be the largest ever health infrastructure investment in Victoria’s history and is due to be completed in 2025.

Additional infrastructure will allow 15,000 more patients to be treated and almost 20,000 extra people to be seen in the emergency department each year.

There will also be a significant increase in mental health beds and more outpatient, palliative care, and surgical services.

Matthew Jinks, CEO of SKS Technologies, said this formal acceptance is a significant achievement for the company.

“Upon execution of the contract, expected to be in the early part of next year, the contract will place the company’s work in hand position in excess of $40 million and provides the business with a strong foundation for future growth and profits,” he said.

SKS Technologies Group Limited (SKS) last traded at $0.18 per share before market open on December 23.

SKS by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…